What is Seaport Therapeutics, Inc. Common Stock?
, a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.07B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.